Why the study?
Does irbesartan improve outcomes in hypertensive patients with metabolic syndrome?
Does irbesartan improve outcomes in hypertensive patients with metabolic syndrome?
This review discusses Russian guidelines and trial data supporting the use of irbesartan for managing arterial hypertension in patients with metabolic syndrome.
May guide irbesartan use in this population per Russian data; leaves open need for confirmatory global trials.
The paper gives the data of Russian guidelines for the diagnosis and approaches to treating metabolic syndrome. It considers the choice of antihypertensive drugs in the treatment of hypertensive patients with metabolic syndrome. The benefits of angiotensin II receptor blockers are shown. The results of a number of trials evaluating the efficacy and safety of irbesartan used to manage arterial hypertension in metabolic syndrome are analyzed.
No takes yet. Share an insight, caveat, or question.
Остроумова et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: